替雷利珠单抗联合紫杉醇+顺铂治疗宫颈癌的临床疗效分析OA
Clinical Efficacy Analysis of Tislelizumab Combined with Paclitaxel and Cisplatin in the Treatment of Cervical Cancer
目的:观察替雷利珠单抗联合紫杉醇+顺铂治疗宫颈癌患者的临床疗效.方法:前瞻性选取 2022 年7月～2024年3月本院收治的146 例宫颈癌患者作为研究对象,按照随机数字表法分为对照组(紫杉醇+顺铂治疗,73例)和观察组(对照组基础上联合替雷利珠单抗治疗,73例).比较两组临床疗效、肿瘤标志物、免疫功能指标、不良反应发生情况及生存情况.结果:观察组治疗总有效率高于对照组(73.97%vs 54.79%,P＜0.05).与治疗前比较,两组治疗后糖类抗原125(CA125)、鳞状细胞癌抗原(SCCA)、癌胚抗原(CEA)和细胞角蛋白19片段抗原21-1(CYFRA21-1)均降低(P＜0.05);与对照组比较,观察组治疗后CA125、SCCA、CEA、CYFRA21-1更低,且治疗前后差值更大(P＜0.05).与治疗前比较,两组治疗后CD3+、CD4+均下降,CD8+均上升(P＜0.05);与对照组比较,观察组治疗后CD3+、CD4+更高,CD8+更低,且治疗前后差值更小(P＜0.05).治疗期间,两组不良反应总发生率比较无统计学差异(P＞0.05).经过1年随访,观察组生存时间长于对照组(11.58个月vs 10.36个月),1年生存率高于对照组(86.30%vs 69.86%).Log-Rank检验显示,两组生存时间、1年生存率比较具有统计学差异(HR=0.390,95%CI:0.185～0.824;χ2=6.714,P=0.010).结论:替雷利珠单抗联合紫杉醇+顺铂可提升宫颈癌疗效,改善免疫功能,延长生存期,且未显著增加不良反应发生风险.
Objective:To observe the clinical efficacy of tislelizumab combined with paclitaxel and cisplatin in the treatment of patients with cervical cancer.Methods:A total of 146 cervical cancer patients admitted to our hospital from July 2022 to March 2024 were prospectively selected as study subjects and divided into the control group(paclitaxel+cisplatin,n=73)and the observation group(control group plus tislelizumab,n=73)according to a random number table method.Clinical efficacy,tumor markers,immune function indicators,adverse reaction rates,and survival outcomes were compared between the two groups.Results:The overall response rate in the observation group was higher than that in the control group(73.97%vs 54.79%,P<0.05).Compared with before treatment,carbohydrate antigen 125(CA125),squamous cell carcinoma antigen(SCCA),carcinoembryonic antigen(CEA),and cytokeratin 19 fragment antigen 21-1(CYFRA21-1)levels decreased in both groups after treatment(P<0.05);compared with the control group,the levels of CA125,SCCA,CEA,and CYFRA21-1 were lower in the observation group after treatment,and the differences between before and after treatment were greater(P<0.05).Compared with before treatment,CD3+and CD4+levels decreased,while CD8+levels increased in both groups after treatment(P<0.05);compared with the control group,CD3+and CD4+levels were higher,and CD8+levels were lower in the observation group after treatment,with smaller differences between before and after treatment(P<0.05).During treatment,there was no significant difference in the overall incidence of adverse reactions between the two groups(P>0.05).After a 1-year follow-up,the observation group had a longer survival time(11.58 months vs 10.36 months)and a higher 1-year survival rate(86.30%vs 69.86%)than the control group.Log-Rank test showed statistical differences in survival time and 1-year survival rate between the two groups(HR=0.390,95%CI:0.185～0.824;χ2=6.714,P=0.010).Conclusion:Tislelizumab combined with paclitaxel and cisplatin can improve the efficacy of cervical cancer treatment,enhance immune function,prolong survival,and does not significantly increase the risk of adverse reactions.
职静静;高敬佩;杨方圆;宋洁洁;翟梦姣;焦瑞仙;孙丽莎
焦作市第二人民医院妇瘤一区,焦作 454000焦作市第二人民医院妇瘤二区,焦作 454000焦作市第二人民医院妇瘤一区,焦作 454000焦作市第二人民医院妇瘤一区,焦作 454000焦作市第二人民医院妇瘤一区,焦作 454000焦作市第二人民医院妇瘤一区,焦作 454000焦作市第二人民医院妇瘤一区,焦作 454000
医药卫生
宫颈癌替雷利珠单抗紫杉醇顺铂肿瘤标志物免疫功能
cervical cancerdurvalumabpaclitaxelcisplatintumor markersimmune function
《中国合理用药探索》 2026 (2)
38-43,6
河南省医学科技攻关计划项目(LHGJ20240697)
评论